Japan Lawmakers will debate legislation as early as this month to make the approval process for cell therapies faster than in the U.S. and U.K
BIG PUSH TO BECOME THE LEADER
Finally the quality competition we need to wake up the FDA
Hold on. Japanese investors might be investing in ACT when they discover that ACTC's trials are going into Phase III. Today, should be an exciting day for ACTC.
Sentiment: Strong Buy
Wow, Fighter, thats something we both agree on, now if congress would just agree on something, anything will do.